ClinicalTrials.gg
CompletedNCT02805374Updated Aug 24, 2016

A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517

A Phase 1 interventional study of ASP1517 in Healthy Subjects, sponsored by Astellas Pharma Inc. Completed at 1 site in Japan. Open to male participants aged 20 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-24.

Sponsored by Astellas Pharma Inc · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
20 Years to 44 Years
Sex
Male
01

Study summary

The objective of this study is to evaluate the effect of food on the pharmacokinetics of a single oral dose of ASP1517 in non-elderly healthy adult male subjects.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Pharmacokinetics
  • ASP1517
  • Food effect
03

In context

Lead sponsor

Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 44 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight: ≥50.0 kg and \<80.0 kg
  • Body-mass index : ≥17.6 and \<26.4 kg/m2
  • Subject must agree to use two of the established methods after acquisition through 84 days after the last administration of the study drug.
  • Subject must agree not to donate sperm after informed consent acquisition through 84 days after the last administration of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Received or is scheduled to receive any drugs in other clinical trials or post-marketing studies within 120 days before screening or during the period from screening to the hospital admission day of Period 1
  • Received or is scheduled to receive medications (including over-the-counter [OTC] drugs) within 7 days before the hospital admission day of Period 1
  • Received or is scheduled to receive supplements within 7 days before the hospital admission day of the Period 1
  • Deviates from any of the normal range of blood pressure, pulse rate, body temperature and standard 12-lead (ECG) at screening or the hospital admission day of Period 1
  • Meets any of the criteria for laboratory tests at screening or the hospital admission day of Period 1. Normal ranges of each test specified at the test/assay organization will be used as the normal ranges in this study.
  • Concurrent or previous drug allergies.
  • Development of (an) upper gastrointestinal symptom(s) within seven days before the hospital admission day of Period 1.
  • Concurrent or previous hepatic disease, heart disease, respiratory disease, gastrointestinal disease, renal disease, endocrine disease, cerebrovascular disorder, malignant tumor, retinal neovascular lesions and macular edema.
  • A history of digestive tract excision.
  • Previous use of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) such as ASP1517 (FG-4592), YM311(FG-2216) or erythropoietin products.
  • Excessive alcohol or smoking habit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    ASP1517 fasting then fed

    Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.

    Drug: ASP1517

  • Experimental
    ASP1517 fed then fasting

    Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.

    Drug: ASP1517

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) parameter of ASP1517 in Plasma: AUCinf

    AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity

    Time frame: Up to Day 4 of each treatment period

  2. PK parameter of ASP1517 in Plasma: Cmax

    Cmax: Maximum concentration

    Time frame: Up to Day 4 of each treatment period

Secondary outcomes

  1. PK parameter of ASP1517 in Plasma: AUClast

    AUClast: Area under the concentration-time curve from the time of dosing to the last measurable concentration

    Time frame: Up to Day 4 of each treatment period

  2. PK parameter of ASP1517 in Plasma: CL/F

    CL/F: Apparent total systemic clearance

    Time frame: Up to Day 4 of each treatment period

  3. PK parameter of ASP1517 in Plasma: λz

    λz: Terminal rate constant

    Time frame: Up to Day 4 of each treatment period

  4. PK parameter of ASP1517 in Plasma: MRTinf

    MRTinf: Mean residence time extrapolated to infinity

    Time frame: Up to Day 4 of each treatment period

  5. PK parameter of ASP1517 in Plasma: t1/2

    t1/2: Terminal elimination half-life

    Time frame: Up to Day 4 of each treatment period

  6. PK parameter of ASP1517 in Plasma: tmax

    tmax: Time of Cmax

    Time frame: Up to Day 4 of each treatment period

  7. PK parameter of ASP1517 in Plasma: tlag

    tlag: Lag time

    Time frame: Up to Day 4 of each treatment period

  8. PK parameter of ASP1517 in Plasma: Vz/F

    Vz/F: Apparent volume of distribution during the terminal elimination phase

    Time frame: Up to Day 4 of each treatment period

  9. PK parameter of ASP1517 in Urine: Ae

    Ae: Cumulative amount of ASP1517 excreted into urine

    Time frame: Up to Day 4 of each treatment period

  10. PK parameter of ASP1517 in Urine: CLR

    CLR: Renal clearance

    Time frame: Up to Day 4 of each treatment period

  11. Safety assessed by adverse events

    Time frame: Up to Day 9 of Period 2

  12. Number of participants with abnormal vital signs and/or adverse events during treatment period

    Time frame: Up to Day 9 of Period 2

  13. Number of participants with abnormal laboratory values and/or adverse events during treatment period

    Time frame: Up to Day 9 of Period 2

  14. Number of participants with abnormal standard 12-Lead ECG and/or adverse events during treatment period

    ECG: Electrocardiogram

    Time frame: Up to Day 9 of Period 2

07

Study locations

1 site
  • Site JP00001
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2016
First posted
Jun 20, 2016
Start
Jul 2016
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Last update
Aug 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02805374
Collaborators
FibroGen
Responsible party
Sponsor
First posted
Jun 20, 2016
Start date
Jul 2016
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Aug 24, 2016

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion